Liu Aijun, Xun Shucan, Zhou Guangzhi, Zhang Yonglin, Lin Li
Department of Cardiology, Binhai People's Hospital, Yancheng, China.
Department of Cardiovascular Medicine, East Hospital, Tongji University School of Medicine, Shanghai, China.
J Pharm Pharmacol. 2023 Mar 12;75(3):397-406. doi: 10.1093/jpp/rgac102.
Honokiol, a natural active compound extracted from Chinese herbal medicine, can ameliorate acute lung and kidney injury of sepsis. This study was to explore the effects of honokiol on sepsis-associated cardiac dysfunction and the underlying mechanism.
Septic mice were induced by cecal ligation and puncture (CLP) or lipopolysaccharide (LPS), and septic HL-1 or AC16 cells were induced by LPS.
Honokiol improved the survival and alleviated cardiac dysfunction in mice with CLP-induced sepsis. Honokiol inhibited the increased interleukin (IL) 1-β, IL-6 and tumour necrosis factor (TNF)-α in the serum and heart of CLP- and LSP-induced septic mice. Honokiol treatment reversed the increased levels of IL1-β, IL-6 and TNF-α in LPS-induced HL-1 cells. Honokiol treatment also decreased the elevated levels of IL1-β, IL-6 and TNF-α in LPS-induced AC16 cells. The increased cardiac apoptosis in CLP- and LPS-induced septic mice was alleviated by honokiol. The enhancement of oxidative stress in the heart of CLP- and LPS-induced septic mice was suppressed after honokiol administration.
These results showed that honokiol could ameliorate sepsis-associated cardiac dysfunction via attenuating inflammation, apoptosis, and oxidative stress. Honokiol is a prospective drug for sepsis-associated heart damage in the future.
厚朴酚是从中药中提取的一种天然活性化合物，可改善脓毒症所致的急性肺损伤和肾损伤。本研究旨在探讨厚朴酚对脓毒症相关性心脏功能障碍的影响及其潜在机制。
采用盲肠结扎穿刺术（CLP）或脂多糖（LPS）诱导脓毒症小鼠，用LPS诱导脓毒症HL-1或AC16细胞。
厚朴酚可提高CLP诱导的脓毒症小鼠的生存率并减轻心脏功能障碍。厚朴酚可抑制CLP和LSP诱导的脓毒症小鼠血清和心脏中白细胞介素（IL）-1β、IL-6和肿瘤坏死因子（TNF）-α水平的升高。厚朴酚处理可逆转LPS诱导的HL-1细胞中IL-1β、IL-6和TNF-α水平的升高。厚朴酚处理还可降低LPS诱导的AC16细胞中IL-1β、IL-6和TNF-α的升高水平。厚朴酚可减轻CLP和LPS诱导的脓毒症小鼠心脏细胞凋亡增加的情况。厚朴酚给药后可抑制CLP和LPS诱导的脓毒症小鼠心脏氧化应激的增强。
这些结果表明，厚朴酚可通过减轻炎症、细胞凋亡和氧化应激来改善脓毒症相关性心脏功能障碍。厚朴酚是未来治疗脓毒症相关性心脏损伤的一种有前景的药物。
